How Biotech CEOs Feel About the Theranos Effect and the Way It's Impacted the Industry
One of the biggest stories in tech and healthcare over the past year and a half has been the saga of Theranos. The blood-testing company once carried a $9 billion valuation and the promise of running multiple tests on just a single drop of blood. But, starting in October 2015, cracks began to show, calling into question its science and its transparency.